Skip to main content

Table 1 Activators of stress-induced gcs-1p::gfp expression and their effects on stress-induced phase 2 gene expression, stress resistance, PMK-1 and SKN-1

From: Genome-wide screening identifies new genes required for stress-induced phase 2 detoxification gene expression in animals

Functional classification of gene targeted by RNAi Intestinalgst-4p::gfpexpression mRNA (Figure2B) Arsenite resistance PMK-1 activation Nuclear levels of SKN-1S393A::GFP
WT (N2) (Additional file1: Table S3) prdx-2(Additional file2: Figure S3) gcs-1 gst-7 (Figure2C) (Figure4) (Figure6A)
Gene expression Human orthologue Proposed function        
C17G10.1 OGFOD1 Regulates translation - - - - -
C35C5.1 sdc-2 GOLGA6L5 Sex determination/dosage compensation ND ND ND ↓*** -
F47A4.2 dpy-22 MED12 Mediator subunit - - ↓* - -
C16A3.8 thoc-2 THOC2 Transcriptional elongation - ↓*** ↓*** ↓* ↓** ↓***
K04G7.11 SYF2 Pre-mRNA-splicing factor - ↓** ↓***
Protein homeostasis          
Y102A5A.1 cand-1 CAND1 Cullin-associated NEDD8-dissociated - ↓*** ↓* - ↓* -
B0025.2 csn-2 CSN2 Cop9 signalosome subunit ↓*** ↓*** ↓* - ↓***
T05H10.5 ufd-2 UBE4B E4 ubiquitin conjugating enzyme ↓*** ↓* - ↓***
Signal transduction          
F13B10.1 tir-1 SARM1 Pathogen responses - ↓*** ↓* ↓*** ↓*** -
T28H11.2 srm-1 - Serpentine receptor - - ↓** - -
ZK792.3 inx-9 - Innexin - - ND ND ND ND -
Growth/metabolism          
C06A8.1 mthf-1 MTHFR Methylenetetrahydrofolate reductase - ↓*** ↓** ↓* -
C34F11.3 AMPD2 AMP deaminase 2 - ↓*** ND ND ND ND -
Structural          
F46E10.11 hpo-26 - Hypersensitive to pore-forming toxin - ↓*** ND ND ↓***
Transport/trafficking          
R11A5.1 apb-3 AP3B1/2 Adaptin - - ↓** ↓*** - ↓***
Unknown function          
F22F7.4 -   - - ↓* ↓* - - -
  1. Sixteen RNAi that prevented any detectable intestinal gcs-1p::gfp expression in prdx-2 mutant animals and in more than 50% of wild-type animals treated with 1 mM arsenite for 90 min (N2 gcs-1p::gfp) on each of three occasions on which they were screened, following quantitative analysis, but which did not reduce intestinal expression of a non-phase 2 reporter gene, F09E5.3::gfp (Additional file 1: Table S3). These genes were placed into categories based on gene ontology [15]. Where RNAi affected gst-4p::gfp expression in wild-type (Additional file 1: Table S3) or prdx-2 mutant animals (Additional file 2: Figure S3) the effect is indicated by an arrow. Where RNAi produced a greater than 10% change in gcs-1 or gst-7 mRNA levels in arsenite-treated animals (Figure 2B), arsenite resistance (Figure 2A,C), PMK-1 phosphorylation in arsenite-treated animals (Figure 4) or levels of SKN-1S393A::GFP in intestinal nuclei (Figure 6A) this is indicated. Statistically significant differences from control animals are indicated (*P < 0.05; **P < 0.01; ***P < 0.001). ND, not determined; RNAi, RNA interference; WT, wild type.